Literature DB >> 11190875

HLA and multiple sclerosis. Studies of a spanish population.

D F Uría1.   

Abstract

INTRODUCTION: Family and population studies have shown the existence of genetic susceptibility to have multiple sclerosis (MS). The genes of the HLA system have been the only genetic markers for this tendency to have been confirmed in multiple studies in different countries. A relation has also been found between certain HLA genes and the clinical course or paraclinical parameters of MS. DEVELOPMENT: In this article we first analyze the structure, function, typing and association of illnesses with the HLA system and their relation with MS. Subsequently we review the articles published or reported on the HLA-MS association in the Spanish population.
CONCLUSION: MS is generally associated with the DR15/DQ6 haplotype (subtypes of DR2/DQ1) in the Spanish population. There may be minor ethnic differences in some regions which explain other associations found. Although the Spanish studies on the association of HLA with clinical and paraclinical factors of MS require confirmation in samples with larger number of patients, the primarily progressive forms and those with a worse prognosis tend to be associated with DR4 and the benign forms with DR2. The DRw 13 (DR6) seems to be a protective allele. The presence of DR2 may be a marker for the development of MS after an optic neuritis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11190875

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  2 in total

1.  Distinct HLA class I and II genotypes and haplotypes are associated with multiple sclerosis in Bahrain.

Authors:  Moudi Al-Nashmi; Safa Taha; Abdel Halim Salem; Isa Alsharoqi; Moiz Bakhiet
Journal:  Biomed Rep       Date:  2018-10-24

2.  HLA-DQ6 (DQB1*0601)-restricted T cells protect against experimental autoimmune encephalomyelitis in HLA-DR3.DQ6 double-transgenic mice by generating anti-inflammatory IFN-gamma.

Authors:  Ashutosh Mangalam; David Luckey; Eati Basal; Marshall Behrens; Moses Rodriguez; Chella David
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.